NCT05507372View on ClinicalTrials.gov

Treatment for Post Acute COVID-19 Syndrome

NAUnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

June 1, 2023

Study Completion Date

December 1, 2023

Conditions
Tinnitus, Subjective
Interventions
DRUG

Pimozide 1 MG

Dopamine Receptor Antagonist - Oral Pimozide

Sponsors
All Listed Sponsors
collaborator

Jupiter Wellness, Inc.

UNKNOWN

lead

Applied Biology, Inc.

INDUSTRY

NCT05507372 - Treatment for Post Acute COVID-19 Syndrome | Biotech Hunter | Biotech Hunter